Original Article

Meta-analysis on the association between CYP1A1 T3801C polymorphism and breast cancer in the Chinese population

Zheng-Yang Xu

Department of Chemo-Radiotherapy, The People’s Hospital of Yinzhou District, Ningbo 315000, China

Received March 18, 2016; Accepted June 12, 2016; Epub August 15, 2016; Published August 30, 2016

Abstract: Although many publications have evaluated the correlation between Cytochrome P450 1A1 (CYP1A1) T3801C polymorphism and breast cancer risk, the results remain inconclusive. In order to derive a more precise estimation of the association, a meta-analysis was performed in the Chinese population. Related studies were identified from PubMed and Chinese databases through December 2015. Pooled odds ratios (ORs) and 95% confidence intervals (CIs) were used to assess the strength of the associations. A total of 14 studies including 2910 BC cases and 3018 controls were involved in this meta-analysis. Overall, significant association was found between CYP1A1 T3801C polymorphism and BC risk when all studies in the Chinese population pooled into this meta-analysis (C vs. T: OR = 1.29, 95% CI = 1.07-1.56; CC vs. TT: OR = 1.71, 95% CI = 1.20-2.45; CC vs. CT: OR = 1.21, 95% CI = 1.03-1.42; CC + CT vs. TT: OR = 1.40, 95% CI = 1.09-1.80; CC vs. TT + CT: OR = 1.46, 95% CI = 1.11-1.92). In subgroup analyses stratified by geographical areas and source of controls, significantly increased risk was found in North China and in population-based studies. In conclusion, this meta-analysis provides the evidence that CYP1A1 T3801C polymorphism may contribute to the BC development in the Chinese population, especially in North China, and further studies in other ethnic groups are required for definite conclusions.

Keywords: Meta-analysis, CYP1A1 T3801C, polymorphism, breast cancer, Chinese

Introduction

Breast cancer (BC) is the most frequently diagnosed cancer and the leading cause of cancer death in females worldwide, accounting for 23% (1.38 million) of the total new cancer cases and 14% (458400) of the total cancer deaths in 2008 [1]. About half the BC cases and 60% of the deaths are estimated to occur in economically developing countries [1]. The mechanisms of BC have not been fully illustrated. Reproductive factors including a long menstrual history, nulliparity, recent use of postmenopausal hormone therapy or oral contraceptives, and late age at first birth, all can increase the risk of breast cancer [2]. Alcohol consumption also has been identified as one of the risk factors for BC [3, 4]. However, only a subset of individuals exposed to these risk factors eventually develop BC, indicating an important role of genetic factors in the BC development.

Many common low-penetrant genes have been identified as potential BC susceptibility genes. Among these, an important one is cytochrome P450 1A1 (CYP1A1), which plays an essential role in the metabolic activation of major classes of tobacco procarcinogen such as aromatic amines and polycyclic aromatic hydrocarbons (PAHs). So it may affect the metabolism of the environmental carcinogens and alter susceptibility to BC. CYP1A1 enzyme is a member of the CYP superfamily and prone to mutation [5]. Agundez [5] revealed an association between CYP1A1 enzyme activity and the risk of developing several types of cancers, including BC. CYP1A1 T3801C polymorphism (MspI, rs4646903), also known as the m1 allele, is most studied. An association between CYP1A1 T3801C polymorphism and BC was first reported by Bailey and co-workers in 1998 in Caucasians and African Americans [6]. As a consequence, many studies have attempted to clarify this relationship, but there has been no
definite consensus to date. Differences in results may be related to the ethnic and clinical heterogeneity of the patients studied or to the relatively small numbers of patients in each study. Meta-analysis is a good way to summarize the available evidence to provide a robust result. For addressing the association between CYP1A1 T3801C polymorphism and BC risk better, we performed a meta-analysis of all eligible studies in the Chinese population to lessen the impact of different genetic background.

Materials and methods

Search strategy and selection criteria

A comprehensive literature search was performed in the PubMed, Chinese Wanfang Data Knowledge Service Platform, Chinese National Knowledge Infrastructure, and Chinese Biology Medicine for relevant articles published with the following Mesh terms: (“Breast Neoplasms” [MeSH] or “breast cancer” or “breast tumor” or “breast carcinoma”) and (“P4501A1” or “CYP1A1”) and (China or Chinese or Taiwan). An upper date limit of December 2015 was applied and no lower date limit was used. The search was performed without any restrictions on language and focused on studies conducted in humans. Concurrently, the reference lists of reviews and retrieved articles were searched manually.

Inclusion criteria: (1) case-control or cohort studies describing the association of CYP1A1 T3801C polymorphism and BC, (2) all patients with the diagnosis of BC confirmed by pathological or histological examination; (3) provides the distribution of CYP1A1 T3801C polymorphism in patients and controls, (4) Chinese participants only. Exclusion criteria: (1) duplicate publications, (2) incomplete data, (3) no control, (4) meta-analyses, letters, reviews, meeting abstract, or editorial articles.

Data extraction

Xu ZY independently extracted data from all included publications. The title and abstract of all potentially relevant articles were screened to determine their relevance. Full articles were also scrutinized if the title and abstract were ambiguous. The following data was collected from each study: first author’s surname, year of publication, geographical areas, source of controls, total numbers of cases and controls, and the numbers of cases and controls who harbored the CYP1A1 T3801C genotypes.

Statistical analysis

The strength of associations between haplotypes of XRCC1 T3801C and risk of breast cancer was assessed according to the odds ratio (OR). The pooled ORs were performed for allele model (C versus T), dominant model (CT + CC versus TT), recessive model (CC versus CT + TT), heterozygous model (CC versus CT) and homozygous model (CC versus TT), respectively. The significance of the pooled OR was determined by the z test. The presence of between-study heterogeneity was investigated using the chi-square-based Cochran’s Q statistic test with P-values < 0.1. Hardy-Weinberg equilibrium (HWE) of controls was calculated by using the goodness-of-fit test, and deviation was considered when P < 0.05. We used the fixed-effects model and the random-effects model.
based on the Mantel-Haenszel method and the DerSimonian and Laird method, respectively, to evaluate the sensitivity analysis. Possible causes of heterogeneity were investigated by subgroup analyses based on geographic areas and source of controls. Begg's funnel plots and
Egger’s linear regression test were used to assess publication bias. All the statistical analysis was conducted using STATA statistical package (version 10, STATA, College Station, TX) and a significance level of $\alpha = 0.05$ was applied.

Results

Eligible studies

Figure 1 graphically illustrates the trial flow chart. A total of 91 articles that examined the association between CYP1A1 polymorphism and risk of BC were identified after document duplication removed in different databases. After screening the titles and abstracts, 71 articles were excluded because they were review articles, meeting abstracts and irrelevant to the current study. Of the 20 potentially relevant articles [7-26] identified for full study retrieval, six [7-12] were excluded due to duplicate studies or no T3801C allele. Finally, 14 studies [13-26] met the inclusion criteria. The publication year of involved studies ranged from 1999 to 2015. In total, 2910 BC cases and 3018 controls were involved in this meta-analysis, which evaluated the relationship between CYP1A1 T3801C polymorphism and BC risk in Chinese. The characteristics of the included studies are summarized in Table 1.

Meta-analysis results

Table 2 lists the primary results. In the total analyses, a significantly elevated risk of BC was associated with all variants of CYP1A1 T3801C (for CC vs TT: OR = 1.71, 95% CI = 1.20-2.45; for CC vs CT: OR = 1.21, 95% CI = 1.03-1.42; for CC and CT combined vs TT: OR = 1.40, 95% CI = 1.09-1.80; for CC vs TT and CT: OR = 1.46, 95% CI = 1.11-1.92). For the allele C versus allele T, the pooled OR was 1.29 (95% CI = 1.07-1.56) (Figure 2). However, there was significant heterogeneity between studies. Hence, we then performed subgroup analyses by geographical areas and source of controls. In the stratified analysis by geographical areas, significantly increased risks were found in the population from North China (C vs: T: OR = 1.65, 95% CI = 11.41-1.93; CC vs: TT: OR = 1.68, 95% CI = 1.89-3.81; CC vs: CT: OR = 1.73, 95% CI = 1.21-2.47; CC + CT vs: TT: OR = 1.83, 95% CI = 1.50-2.22; CC vs: TT + CT: OR = 2.19, 95% CI = 1.57-3.06), but not found in the South China. In the stratified analysis by source of controls, significantly increased risks were found in the population-based studies (C vs: TT: OR = 1.26, 95% CI = 1.05-1.53; CC vs: TT: OR = 1.64, 95% CI = 1.14-2.35; CC vs: CT: OR = 1.20, 95% CI = 1.02-1.41; CC vs: TT + CT: OR = 1.42, 95% CI = 1.08-1.87) and hospital-based studies (CC + CT vs: TT: OR = 2.22, 95% CI =1.49-3.32).

Sensitive analysis and bias diagnosis

In order to compare the difference and evaluate the sensitivity of the meta-analyses, we used both models (the fixed-effects model and random-effects model) to evaluate the stability of the meta-analysis. All the significant results were not materially altered (Table 2). Hence, results of the sensitivity analysis suggest that the data in this meta-analysis are relatively stable and credible.

The Begg’s funnel plot and Egger’s test was performed to assess the publication bias of literatures. The shape of the funnel plots did reveal obvious asymmetry (Figure 3). Then, the Egger’s test was used to provide statistical evidence of funnel plot symmetry. The Egger’s test indicated that there was publication bias under
Discussion

Although the multifactorial nature of cancer is well known, genetic factors are considered to be strong determinants of these diseases, thus encouraging researchers to search for the responsible genes. Since the first negative association between CYP1A1 T3801C and BC was reported [6], many studies have been undertaken to investigate the association. However, results of individual studies were inconclusive. Recently, one meta-analysis has reported that there was significant association between CYP1A1 T3801C polymorphism and BC risk only in South Indian [27], while another three meta-analyses reported that CYP1A1 T3801C polymorphism is not associated with BC risk [28-30]. Regional and racial differences is one likely reason for the conflict results. Therefore, we conducted this meta-analysis to derive a more precise estimate of the association between CYP1A1 T3801C and susceptibility to BC in the Chinese population, in order to lessen the impact of regional and racial differences.

Our meta-analysis involved 14 case-control studies, including 2910 BC cases and 3018 controls. Results showed a significant association between the CYP1A1 T3801C polymorphism and BC in the total analyses. In the sub-group analyses stratified by geographical areas and source of controls, significantly increased association was found in North China, in population-based and hospital-based studies, but not found in South China. This result suggested the differences in genetic backgrounds, the environment they lived in may influence the association between CYP1A1 T3801C polymorphism and BC risk.

Compared to the previous meta-analyses [27-30], they did not search Chinese databases, and included a smaller number of studies, which were conducted in Chinese populations than ours did. Therefore, our study has higher statistical power than other meta-analyses conducted in other ethnic groups. The effects of gene-environment interactions with respect to BC risk were also conducted by sub-group analyses in this meta-analysis. To our knowledge, this study represents the first meta-analysis of the association of CYP1A1 T3801C variants with BC in the Chinese population using such a large sample size. In addition, the test of the HWE for distribution of the genotypes in control groups suggested that there was no significantly different genetic background among the participants. The sensitivity analysis confirmed the reliability and stability of the meta-analysis. Therefore, the findings from our meta-analysis provide a strong evidence for the association between CYP1A1 T3801C polymorphism and BC in the Chinese population, especially in North China.

Although our study has obvious strengths, several limitations should be considered. First, the ethnic-specific meta-analysis only included data from Chinese patients with BC, and thus, our results are only applicable to this ethnic group. Second, since this meta-analysis was based primarily on unadjusted effect estimates and CIs, confounding factors were not controlled. Third, although we minimized this likelihood by searching all the databases related, publication bias nevertheless existed in our study.
In conclusion, this meta-analysis demonstrates that CYP1A1 T3801C polymorphism might contribute to individual susceptibility to BC in the Chinese population. Further studies are needed to determine if the CYP1A1 T3801C gene confers a risk of BC in other ethnic groups. BC is a multifactorial disease caused by not only genetic factors but also environmental factors, and studies analyzing gene-gene and gene-environment interactions are required to confirm our results. Such studies may eventually lead to have a better, comprehensive understanding of the association between the CYP1A1 T3801C polymorphism and BC risk.

Disclosure of conflict of interest

None.

Address correspondence to: Zheng-Yang Xu, Department of Chemo-Radiotherapy, The People’s Hospital of Yinzhou District, No. 251, Baizhang East Road, Ningbo 315000, China. Tel: +86 574 87017561; Fax: +86 574 87017561; E-mail: nbxuzhy@126.com

References

CYP1A1 T3801C and BC in Chinese


